ATS (ATS) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
4 Feb, 2026Executive summary
Q3 revenues rose 16.7% year-over-year to $761 million, driven by 12.6% organic growth and FX benefits, with strong performance in most segments except transportation.
Adjusted earnings from operations were $79.9 million, with a 10.5% margin, and adjusted EBITDA reached $105.2 million, up 20.2% year-over-year.
Net income surged to $30.0 million, with basic EPS at $0.31, and adjusted EPS at $0.48.
Order Bookings were $821 million, down 7% year-over-year but up 12% sequentially, while Order Backlog remained robust at $2,053 million.
CEO Doug Wright appointed, with a CFO transition and leadership changes in key segments.
Financial highlights
Q3 revenues were $760.7 million, up $108.7 million or 16.7% year-over-year, with 13% organic growth.
Adjusted earnings from operations were $79.9 million, up 21.6% from Q3 last year, with a margin of 10.5%.
Net income for Q3 was $30.0 million, up 361.5% year-over-year; basic EPS increased to $0.31 from $0.07.
Adjusted EBITDA was $105.2 million, a 20.2% increase year-over-year, with a margin of 13.8%.
Free cash flow for Q3 was $98.0 million, nearly doubling year-over-year.
Outlook and guidance
Q4 revenues are expected between $710 million and $750 million, supported by a $2.1 billion order backlog.
Margin expansion initiatives are ongoing to offset inflation and supply chain pressures.
Year-to-date revenue growth is 13.6%, with 8% organic growth.
Adjusted earnings from operations up 14% year-to-date.
Management expects backlog to help mitigate short-term variability in bookings.
Latest events from ATS
- Margin expansion, portfolio diversification, and disciplined M&A drive future growth plans.ATS
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Life sciences and nuclear energy drive growth, with disciplined M&A and resilient market focus.ATS
Raymond James 46th Annual Institutional Investors Conference3 Feb 2026 - Order bookings surged 18.4% as life sciences growth offset transportation softness.ATS
Q1 20252 Feb 2026 - Tripled revenue, tech innovation, and services expansion drive growth in life sciences and EV.ATS
Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - Strategic focus on regulated markets, M&A, and technology drives growth and innovation.ATS
15th Annual Global Materials & Industrials Conference31 Jan 2026 - Growth in life sciences and digital services, with GLP-1 and auto-injectors as key drivers.ATS
Jefferies Global Industrial Conference22 Jan 2026 - Q2 revenue fell 17% as life sciences bookings hit a record, offsetting transportation weakness.ATS
Q2 202516 Jan 2026 - Life sciences and food lead growth as margin targets and innovation remain central priorities.ATS
Scotiabank Transportation & Industrials Conference14 Jan 2026 - High-value automation in life sciences and food safety drives growth and margin expansion.ATS
UBS Global Industrials and Transportation Conference12 Jan 2026